# EVM14

Source: https://onco.cc/drugs/evm14/  
OnCo record `evm14` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EVM14 is a cancer vaccine from Everest Medicines (Beijing) Co., Ltd., in registered phase 2 trials for metastatic cancer.

## Summary

EVM14 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Everest Medicines (Beijing) Co., Ltd., in metastatic cancer. A cancer vaccine, as described in the registry record: it trains the immune system against tumour antigens. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: EVM14
- Modality: Cancer vaccine
- Mechanism: A cancer vaccine, as described in the registry record: it trains the immune system against tumour antigens.

## Sources

- ClinicalTrials.gov: trials of EVM14: https://clinicaltrials.gov/search?intr=EVM14

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- trials: [Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors](https://onco.cc/trials/nct07095868/)

---
JSON: https://onco.cc/api/v1/entities/evm14.json